◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › LEXX

Lexaria Bioscience Corp. (LEXX) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-20

Lexaria Bioscience Corp. (LEXX) operates in the Biotechnology industry and is headquartered in Kelowna, Canada with about 7 employees. Its market capitalization is roughly $16 million. In the fiscal year ended 2025-08-31, LEXX reported $1M in revenue and ($12M) in net income.

Lexaria Bioscience Corp. operates as a biotechnology company.

Interactive charts & full statements → Open the LEXX valuation workbench →

LEXX Revenue & Earnings History — Annual Income Statement

Income statement2025-08-312024-08-312023-08-312022-08-312021-08-31
Total Revenue$1M$0M$0M$0M
Gross Profit$1M$0M$0M$0M
Operating Income (EBIT)($12M)($6M)($6M)($7M)
Net Income($12M)($6M)($7M)($7M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

LEXX Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-05-312026-02-282025-11-302025-08-312025-05-312025-02-282024-11-30
Total Revenue$0M$0M$0M$0M$0M
Gross Profit$0M$0M$0M$0M$0M
Operating Income (EBIT)($2M)($2M)($3M)($4M)($3M)
Net Income($1M)($2M)($3M)($4M)($3M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

LEXX Free Cash Flow History

LEXX Balance Sheet History

Balance sheet2025-08-312024-08-312023-08-312022-08-312021-08-31
Total Assets$4M$9M$3M$8M
Total Liabilities$2M$1M$0M$0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive LEXX viewer.

Other Companies in Biotechnology

← LEVIAll stocksLFAC →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.